German state unexpectedly approves first gene trials
نویسندگان
چکیده
منابع مشابه
China approves world's first oncolytic virus therapy for cancer treatment.
Oncolytic virus research got a welcome boost last November when Chinese regulators approved the world’s fi rst oncolytic viral therapy for cancer, Shanghai Sunway Biotech’s genetically modifi ed adenovirus H101. “ It’s fantastic for the fi eld, ” said John Bell , Ph.D., of the Ottawa Health Research Institute in Canada. “ We needed to have something that was a success, and so I think this is a ...
متن کاملFinite-State Parsing of German
There has been a remarkable revival of finite-state methods in linguistics over the last twenty-five years. This renewed interest is a direct consequence of the pioneering work on two-level phonology and morphology by Kimmo Koskenniemi (Koskenniemi, 1983) and of the independently developed approach to finite-state morphology by Ron Kaplan and Martin Kay (Kaplan and Kay, 1994). Based on mathemat...
متن کاملU.S. FDA Approves Biogen’s SPINRAZATM (nusinersen), The First Treatment for Spinal Muscular Atrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE [2])--The U.S. Food and Drug Administrat ion (FDA) approved Biogen’s [3] (NASDAQ: BIIB) SPINRAZATM (nusinersen) under Priority Review for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA is the first and only treatment approved in the U.S. for SMA, a leading genetic cause of death in infants and toddlers that is marked by ...
متن کاملFirst Trials in Webocracy
The Webocracy project aims to empower citizens with innovative communication, access and polling system, supporting increased participation in democratic processes. One of the main project goals is to develop an open source web-based system called WEBOCRAT as a multi-channel communication platform supporting egovernment and e-democracy applications. Some of the WEBOCRAT modules are already avai...
متن کاملU.S. FDA Approves Biogen’s SPINRAZATM (nusinersen), The First Treatment for Spinal Muscular Atrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE [2])--The U.S. Food and Drug Administrat ion (FDA) approved Biogen’s [3] (NASDAQ: BIIB) SPINRAZATM (nusinersen) under Priority Review for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA is the first and only treatment approved in the U.S. for SMA, a leading genetic cause of death in infants and toddlers that is marked by ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature
سال: 1992
ISSN: 0028-0836,1476-4687
DOI: 10.1038/360702a0